Scribe Therapeutics began a run of 2026 gene-editing IPOs by pricing a $128.7 million offering (upsized from earlier indications) to support in vivo CRISPR-based programs. The gene editor is focusing first on lipid-lowering genetic medicine, with its lead asset STX-1150 designed to silence PCSK9 and an Australian Phase 1 trial now enrolling. The IPO proceeds also include plans to advance additional cardiovascular pipeline assets, including PCSK9-adjacent and other genetic targets implicated in atherosclerotic disease. Coverage emphasizes the company’s emphasis on translating genetic medicines beyond rare diseases toward more common chronic indications. For biotech market structure, the Scribe listing marks a notable reopening for IPO momentum in gene editing after a multi-year quiet period. It also underlines how investors continue to reward platforms that couple CRISPR delivery strategies with clear, clinical-stage target selection and near-term trial catalysts.